company background image
SNGX

Soligenix NasdaqCM:SNGX Stock Report

Last Price

US$0.56

Market Cap

US$24.2m

7D

-3.4%

1Y

-30.0%

Updated

04 Dec, 2022

Data

Company Financials +
SNGX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SNGX Stock Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

Soligenix, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Soligenix
Historical stock prices
Current Share PriceUS$0.56
52 Week HighUS$1.00
52 Week LowUS$0.38
Beta1.76
1 Month Change-15.16%
3 Month Change-22.22%
1 Year Change-30.00%
3 Year Change-52.54%
5 Year Change-71.72%
Change since IPO-99.63%

Recent News & Updates

Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma

Oct 05

U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer

Sep 12

Recent updates

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Sep 06
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Apr 22
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?

Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Jan 03
Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?

Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Sep 17
Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now

Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Aug 30
Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?

Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

May 08
Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?

What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Mar 16
What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Nov 20
Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters

Shareholder Returns

SNGXUS BiotechsUS Market
7D-3.4%4.2%1.5%
1Y-30.0%-7.4%-14.9%

Return vs Industry: SNGX underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: SNGX underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is SNGX's price volatile compared to industry and market?
SNGX volatility
SNGX Average Weekly Movement9.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: SNGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SNGX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714Christopher Schaberhttps://www.soligenix.com

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.

Soligenix, Inc. Fundamentals Summary

How do Soligenix's earnings and revenue compare to its market cap?
SNGX fundamental statistics
Market CapUS$24.21m
Earnings (TTM)-US$14.75m
Revenue (TTM)US$858.50k

28.2x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SNGX income statement (TTM)
RevenueUS$858.50k
Cost of RevenueUS$650.66k
Gross ProfitUS$207.84k
Other ExpensesUS$14.96m
Earnings-US$14.75m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.34
Gross Margin24.21%
Net Profit Margin-1,717.96%
Debt/Equity Ratio958.1%

How did SNGX perform over the long term?

See historical performance and comparison